Xilio Therapeutics (XLO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Xilio Therapeutics (XLO) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.09 of bullish evidence against -0.36 bearish.

Xilio Therapeutics last closed at $9.01, +1.12% on the session.

Against the IVW growth benchmark the position is +0.20% over the forecast window.

The read is built from 11 underlying insights — 4 bullish and 7 bearish.

Agreement across those insights is 64%.

15 graded predictions for XLO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Xilio Therapeutics in the 18th percentile on return on equity, where 100 is best.

Xilio Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $59.29M.

StockMap tracks Xilio Therapeutics as the 278th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Xilio Therapeutics ranks 178th of 344 in the group, against a group median of -0.21.